Humacyte (NASDAQ:HUMA) Given Buy Rating at HC Wainwright

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 400.00% from the stock’s previous close.

A number of other research analysts also recently commented on the stock. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Humacyte presently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Up 3.4 %

Shares of NASDAQ:HUMA opened at $3.00 on Wednesday. The business has a fifty day simple moving average of $4.09 and a 200-day simple moving average of $4.77. Humacyte has a 52 week low of $2.81 and a 52 week high of $9.97. The company has a market cap of $377.58 million, a P/E ratio of -2.24 and a beta of 1.36.

Hedge Funds Weigh In On Humacyte

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp raised its holdings in Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after buying an additional 1,895,529 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Humacyte in the third quarter worth $596,000. Thrivent Financial for Lutherans purchased a new position in shares of Humacyte in the 3rd quarter valued at $712,000. Barclays PLC lifted its holdings in shares of Humacyte by 177.6% during the 3rd quarter. Barclays PLC now owns 236,742 shares of the company’s stock valued at $1,288,000 after acquiring an additional 151,458 shares in the last quarter. Finally, Brookstone Capital Management purchased a new stake in Humacyte during the 4th quarter worth $56,000. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.